Good news | Xingyue Biotechnology has been awarded the 2024 Innovation Strategy Source Achievement Transformation Demonstration Enterprise

On March 7th, the 2025 High Quality Economic Development Conference of Wuchang Street in Yuhang District was successfully held. With the theme of "climbing high and forging ahead", the conference comprehensively summarized the economic work achievements in 2024, and commended exemplary organization with outstanding performance in industrial economy. Xingyue Biotechnology has been awarded the title of "2024 Innovation Strategy Source Achievement Transformation Demonstration Enterprise" for its innovation and transformation effectiveness in the field of biomedical materials.

The conference emphasized that Wuchang Street is guided by the "12149" high-quality development plan, implementing an innovation driven development strategy, and promoting the deep integration of the real economy and the digital economy. The innovative development path of Xingyue Biotechnology is highly in line with regional planning, with 20 years of deep cultivation in the field of medical silk materials. It has broken through core technologies such as silk fibroin purification, molecular recombination, and crystallization film formation, and has accumulated 20 authorized invention patents. It has developed nearly 10 types of innovative products such as silk fibroin membrane dressings and silk fibroin hernia repair patches, which have been applied in fields such as wound repair, soft tissue regeneration, and medical beauty regeneration, injecting strong momentum into the regional biopharmaceutical industry cluster.

At present, relevant policies in China's biopharmaceutical industry are constantly being introduced, clarifying the vigorous development of the bioeconomy. The Ministry of Industry and Information Technology and the National Medical Products Administration have jointly launched the "Second Batch of Biomedical Material Innovation Tasks Unveiling and Leading the Way" work, listing silk fibroin as a key research and development direction for polymer materials. This provides national level research and development endorsement and market expansion opportunities for local biomedical material enterprises such as Xingyue Biotechnology. With the support of relevant policies, Xingyue Biotechnology uses medical silk materials as incisions to connect the "basic research clinical verification achievement landing" chain, undertake 6 scientific research projects at or above the provincial level, participate in the drafting of the silk fibroin raw material industry standard YY/T1950-2024 "Tissue Engineering Medical Device Silk Protein", standardize the performance, packaging, transportation and other requirements of silk fibroin, and promote the standardized development of the industry. Xingyue Biotechnology has demonstrated its innovative logic of "technology accumulation+policy protection+ecological empowerment" through its growth path.

This recognition is not only a recognition of the phased achievements of Xingyue Biotechnology, but also an incentive for the company to climb new heights in regenerative medicine. Xingyue Biotechnology will take on the responsibility of "climbing higher and pursuing new", play a leading role as a demonstration enterprise, deepen the layout of cutting-edge fields such as sports medicine and regenerative medicine, closely follow the innovation ecology of government enterprise collaboration, and help Yuhang build a highland of life and health science and technology innovation.